# Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

> **NCT00299702** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 355 (actual)

## Conditions studied

- Schizophrenia
- Psychotic Disorders

## Interventions

- **DRUG:** Abilify
- **DRUG:** Risperidal Consta

## Key facts

- **NCT ID:** NCT00299702
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2011-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299702, "Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00299702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*